Demonstrating an overall survival benefit remains crucial for Macrogenics’ anti-Her2 antibody margetuximab, for regulatory approval and any partnering deals alike.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,